Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
West China Hospital Sichuan University currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners but are concentrated within 1 distinct art unit. This suggests that while different individuals are reviewing the applications, the technical subject matter is closely related and falls under the same administrative group at the patent office.
VAN DRUFF, SYDNEY is identified as one of the busiest examiners for the entity, currently overseeing 1 pending office action. Since there are 2 distinct examiners, each is handling 1 of the 2 pending office actions. The use of 1 distinct art unit indicates that the prosecution is currently confined to a single specialized group. This allows the company to maintain a consistent understanding of the art unit's general examination trends while interacting with the assigned staff to resolve the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN DRUFF, SYDNEY | 1 | 55.0% | +31.7% |
| FISHER, MELISSA L | 1 | 44.2% | +41.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18338477 | Paclitaxel Prodrug, Preparation Method and Application Thereof | FISHER, MELISSA L | 30d |
| 18571541 | PREPARATION AND APPLICATION OF CHIMERIC ANTIGEN RECEPTOR IMMUNE CELL CONSTRUCTED ON BASIS OF LOX1 | VAN DRUFF, SYDNEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18338477 | Paclitaxel Prodrug, Preparation Method and Application Thereof | FISHER, MELISSA L | 30d |
| 18571541 | PREPARATION AND APPLICATION OF CHIMERIC ANTIGEN RECEPTOR IMMUNE CELL CONSTRUCTED ON BASIS OF LOX1 | VAN DRUFF, SYDNEY | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571541 | PREPARATION AND APPLICATION OF CHIMERIC ANTIGEN RECEPTOR IMMUNE CELL CONSTRUCTED ON BASIS OF LOX1 | VAN DRUFF, SYDNEY | — | §103§112 | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18338477 | Paclitaxel Prodrug, Preparation Method and Application Thereof | FISHER, MELISSA L | 1658 | §102§103§112 | Final Rejection | 30d | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial